Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 218

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Sevoflurane for Sedation in Acute Respiratory Distress Syndrome. A Randomized Controlled Pilot Study

Jabaudon, Matthieu, Boucher, Pierre, Imhoff, Etienne, Chabanne, Russell, Faure, Jean-Sébastien, Roszyk, Laurence, Thibault, Sandrine, Blondonnet, Raiko, Clairefond, Gael, Guérin, Renaud, Perbet, Sébastien, Cayot, Sophie, Godet, Thomas, Pereira, Bruno, Sapin, Vincent, Bazin, Jean-Etienne, Futier, Emmanuel, Constantin, Jean-Michel · 2017 · American Journal of Respiratory and Critical Care Medicine

Abstract

Abstract Rationale Sevoflurane improves gas exchange, and reduces alveolar edema and inflammation in preclinical studies of lung injury, but its therapeutic effects have never been investigated in acute respiratory distress syndrome (ARDS). Objectives To assess whether sevoflurane would improve gas exchange and inflammation in ARDS. Methods We did a parallel, open-label single-center randomized controlled trial at three intensive care units from a French university hospital between April 2014 and February 2016. Adult patients were randomized within 24 hours of moderate-to-severe ARDS onset to receive either intravenous midazolam or inhaled sevoflurane for 48 hours. The primary outcome was the PaO2/FiO2 ratio on Day 2. Secondary endpoints included alveolar and plasma levels of cytokines and soluble form of the receptor for advanced glycation end-products, and safety. Investigators who did the analyses were masked to group allocation. Analysis was by intention to treat. Measurements and Main Results Twenty-five patients were assigned to the sevoflurane group and 25 to the midazolam group. On Day 2, PaO2/FiO2 ratio was higher in the sevoflurane group than in the midazolam group (mean ± SD, 205 ± 56 vs. 166 ± 59, respectively; P = 0.04). There was a significant reduction over time in cytokines and soluble form of the receptor for advanced glycation end-products levels in the sevoflurane group, compared with the midazolam group, and no serious adverse event was observed with sevoflurane. Conclusions In patients with ARDS, use of inhaled sevoflurane improved oxygenation and decreased levels of a marker of epithelial injury and of some inflammatory markers, compared with midazolam. Clinical trial registered with www.clinicaltrials.gov (NCT 02166853).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201604-0686oc

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 218

Metadata

Authors
Jabaudon, M., Boucher, P., Imhoff, E., Chabanne, R., Faure, J.-S., Roszyk, L., Thibault, S., Blondonnet, R., Clairefond, G., Guérin, R., Perbet, S., Cayot, S., Godet, T., Pereira, B., Sapin, V., Bazin, J.-E., Futier, E., & Constantin, J.-M.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2017-03-15
Volume
195
Issue
6
Pages
792-800
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2512780017
Cited by
218
References
6
FWCI
8.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sevoflurane for Sedation in Acute Respiratory Distress Syndrome. A Randomized Controlled Pilot Study. https://app.cochat.ai/papers/10.1164/rccm.201604-0686oc
The paper
Jabaudon, M., Boucher, P., Imhoff, E., Chabanne, R., Faure, J.-S., Roszyk, L., Thibault, S., Blondonnet, R., Clairefond, G., Guérin, R., Perbet, S., Cayot, S., Godet, T., Pereira, B., Sapin, V., Bazin, J.-E., Futier, E., & Constantin, J.-M. (2017). Sevoflurane for Sedation in Acute Respiratory Distress Syndrome. A Randomized Controlled Pilot Study. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201604-0686oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.